Friday, August 3, 2018

Privately held Celtaxsys Inc said on Thursday a mid-stage trial testing its experimental cystic fibrosis treatment was successful in reducing a key symptom of the genetic lung disease, but did not improve lung function.


from Reuters: Health News https://ift.tt/2LVRuSx

Related Posts:

  • LATEST HEALTH NEWSAn advisory panel to the U.S. Food and Drug Administration on Friday recommended Sage Therapeutics Inc's experimental treatment for postpartum depression, saying the benefits of the drug outweighed risks. from Reuters: H… Read More
  • LATEST HEALTH NEWS(Reuters Health) - Standing above the crowd puts people at greater risk of developing varicose veins, a large genetic study suggests. from Reuters: Health News https://ift.tt/2RyaN3K … Read More
  • LATEST HEALTH NEWS(Reuters Health) - Teens seeking to buy emergency contraception at pharmacies continue to face significant roadblocks, a new U.S. study suggests. from Reuters: Health News https://ift.tt/2PEljsK … Read More
  • LATEST HEALTH NEWSThe U.S. Food and Drug Administration on Friday approved AcelRx Pharmaceuticals Inc's opioid-based treatment for pain to be used under strict medical supervision, with the agency's chief highlighting reasons for the approval … Read More
  • LATEST HEALTH NEWSTrevena Inc shares plunged 45 percent on Friday after the U.S. Food and Drug Administration declined to approve its opioid injection for managing acute pain, citing inadequate safety data. from Reuters: Health News https… Read More

0 comments:

Post a Comment

Followers

Contact Form

Name

Email *

Message *

Popular Posts

FOLLOW BY EMAIL

Enter your email address:

Delivered by FeedBurner